Back To TopGet Opthea Updates

Mark O’Neill was appointed Vice President CMC in January 2022.  Mr. O’Neill was most recently head of Process Development for Avexis Gene therapies where he orchestrated all product development and technical operations activities pertaining to the startup and licensure of Zolgensma drug substance manufacturing at the Colorado site.  Prior to Avexis, he was Vice President and General Manager of the Thermo Fisher Groningen Single Use Biologics Manufacturing Facility in Groningen, The Netherlands, where he oversaw all operations including startup of commercial manufacturing and initial commercial licensure at the facility.  Mr. O’Neill has over 30 years of experience in the manufacturing of biopharmaceuticals including 20 years with Amgen where he gained extensive experience in all aspects of lifecycle management including Quality, Engineering, Production, Development, Supply Chain and Business Development.

Mark holds a Masters of Science Degree from Colorado School of Mines in Environmental and Chemical Engineering and a Bachelor’s of Science Degree in Chemical Engineering from the University of Colorado.